9-Mar-2026 7:14 AM CST - Yahoo Finance UK Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of +77.78% and +280.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
17-Nov-2025 8:50 PM CST - Yahoo Finance UK Editas Medicine Announces Third Quarter 2025 Results and Business Updates In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027,
10-Nov-2025 6:52 AM CST - Yahoo Finance Editas: Q3 Earnings Snapshot Editas Medicine Inc. EDIT) on Monday reported a loss of $25.1 million in its third quarter.
29-Sep-2025 12:14 AM CST - Yahoo Finance Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a "Buy" rating on the stock and a $5 price target. The positive stance follows the nomination of EDIT-401 as the company's lead Vivo program.
2-Sep-2025 5:22 AM CST - Yahoo Finance Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth? Given this risk, we thought we'd take a look at whether Editas Medicine (NASDAQ:EDIT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow).
12-Aug-2025 3:25 PM CST - Yahoo Finance Editas: Q2 Earnings Snapshot Editas Medicine Inc. EDIT) on Tuesday reported a loss of $53.2 million in its second quarter.
9-Mar-2026 7:14 AM CST - Yahoo Finance UK Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of +77.78% and +280.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
17-Nov-2025 8:50 PM CST - Yahoo Finance UK Editas Medicine Announces Third Quarter 2025 Results and Business Updates In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027,
10-Nov-2025 6:52 AM CST - Yahoo Finance Editas: Q3 Earnings Snapshot Editas Medicine Inc. EDIT) on Monday reported a loss of $25.1 million in its third quarter.
29-Sep-2025 12:14 AM CST - Yahoo Finance Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a "Buy" rating on the stock and a $5 price target. The positive stance follows the nomination of EDIT-401 as the company's lead Vivo program.
2-Sep-2025 5:22 AM CST - Yahoo Finance Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth? Given this risk, we thought we'd take a look at whether Editas Medicine (NASDAQ:EDIT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow).
12-Aug-2025 3:25 PM CST - Yahoo Finance Editas: Q2 Earnings Snapshot Editas Medicine Inc. EDIT) on Tuesday reported a loss of $53.2 million in its second quarter.
